Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change

References

• Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim Care 2003;30:465–91
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Drugs on the horizon for diabesity. Curr Diab Rep 2005;5:353–9
   PubMedGoogle Scholar
• Bulpitt CJ, Palmer AJ, Battersby C, et al. Association of symptoms of type 2 diabetic patients with severity of disease, obesity, and blood pressure. Diabetes Care 1998;21:111–15
   PubMed Web of Science ®Google Scholar
• Heller S. Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2004;65 (Suppl 1):S23–7
   PubMedGoogle Scholar
• Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003;2:33–47
   PubMedGoogle Scholar
• Scheen AJ. Treatment of diabetes in patients with severe obesity. Biomed Pharmacother 2000;54:74–9
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Aggressive weight reduction treatment in the management of type 2 diabetes. Diabetes Metab 1998;24:116–23
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Shaper AG. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 1999;22:1266–72
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Sismanidis C, Carey IM, et al. Trends in the prevalence and management of diagnosed type 2 diabetes 1994–2001 in England and Wales. BMC Fam Pract 2005;6:13
   PubMedGoogle Scholar
• Ford ES, Mokdad AH, Giles WH, et al. Geographic variation in the prevalence of obesity, diabetes, and obesity-related behaviors. Obes Res 2005;13:118–22
   PubMedGoogle Scholar
• Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of over-weight and obesity among US children, adolescents, and adults, 1999–2002. JAMA 2004;291:2847–50
   PubMed Web of Science ®Google Scholar
• King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21: 1414–31
   Google Scholar
• Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991–1998. JAMA 1999;282:1519–22
   PubMed Web of Science ®Google Scholar
• Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990–1998. Diabetes Care 2000;23: 1278–83
   Google Scholar
• Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195–200
   PubMed Web of Science ®Google Scholar
• Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76–9
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Morrato EH, Ghushchyan V, et al. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000–2002. Diabetes Care 2005;28: 1599–603
   Google Scholar
• Swan G. Findings from the latest National Diet and Nutrition Survey. Proc Nutr Soc 2004;63:505–12
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Prevalence of overweight and obesity among adults with diagnosed diabetes – United States, 1988–1994 and 1999–2002. MMWR Morb Mortal Wkly Rep 2004;53: 1066–8
   Google Scholar
• Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997;20:1744–66
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977–86
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–53
   Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854–65
   Google Scholar
• Garrow JS, Webster J. Quetelet’s index (W/H2) as a measure of fatness. Int J Obes 1985;9:147–53
   PubMed Web of Science ®Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217–30
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22: 340–9
   Google Scholar
• Lloyd A, Sawyer W, Hopkinson P. Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Health 2001;4: 392–400
   Google Scholar
• Zhou H, Isaman DJ, Messinger S, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 2005;28:2856–63
   PubMed Web of Science ®Google Scholar
• Lee AJ, Morgan CL, Morrissey M, et al. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetes. Diabet Med 2005;22:1482–6
   PubMed Web of Science ®Google Scholar
• Lean ME, Powrie JK, Anderson AS, et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990;7:228–33
   PubMed Web of Science ®Google Scholar
• Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499–504
   PubMed Web of Science ®Google Scholar
• Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987;147:1749–53
   PubMed Web of Science ®Google Scholar
• Feeny D, Barr RD, Furlong W, et al. Quality of life of the treatment process in pediatric oncology: an approach to measurement. In: Osaba D, ed. Effect of Cancer on Quality of Life. Boca Raton, FL: CRC Press, 1991
   Google Scholar
• Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999;2:113–27
   Google Scholar
• Patrick DL, Chiang YP. Measurement of health outcomes in treatment effectiveness evaluations: conceptual and methodological challenges. Med Care 2000;38 (Suppl 9):II14–25
   Google Scholar
• Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev Pharmacoeconomics Res 2002;2:99–108
   PubMedGoogle Scholar
• Gafni A. The standard gamble method: what is being measured and how it is interpreted. Health Serv Res 1994;29:207–24
   PubMed Web of Science ®Google Scholar
• Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1–30
   PubMed Web of Science ®Google Scholar
• Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989;5:559–75
   PubMedGoogle Scholar
• Brandle M, Herman WH. The CORE Diabetes Model. Curr Med Res Opin 2004;20 (Suppl 1):S1–3
   PubMedGoogle Scholar
• Gold MR, Siegel JE, Russell LB, et al., eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996
   Google Scholar
• Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value Health 2003;6:9–17
   PubMed Web of Science ®Google Scholar
• Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251–64
   Google Scholar
• Herman WH, Hoerger TJ, Brandle M, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323–32
   PubMed Web of Science ®Google Scholar
• McEwan P, Peters JR, Bergenheim K, et al. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin 2006;22:121–9
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Lammert M, et al. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. Curr Med Res Opin 2004;20 (Suppl 1):S41–51
   PubMedGoogle Scholar
• Warren E, Weatherley-Jones E, Chilcott J, et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004;8:1–57
   Web of Science ®Google Scholar
• Wee CC, Hamel MB, Davis RB, et al. Assessing the value of weight loss among primary care patients. J Gen Intern Med 2004;19:1206–11
   PubMed Web of Science ®Google Scholar
• Carey MP, Jorgensen RS, Weinstock RS, et al. Reliability and validity of the appraisal of diabetes scale. J Behav Med 1991;14:43–51
   PubMed Web of Science ®Google Scholar
• Grootenhuis PA, Snoek FJ, Heine RJ, et al. Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med 1994;11:253–61
   PubMed Web of Science ®Google Scholar
• Brooks R, Rabin R, de Charro F, eds. The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Dordrecht: Kluwer Academic Publishers, 2003
   Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108
   PubMed Web of Science ®Google Scholar
• Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337–43
   PubMed Web of Science ®Google Scholar
• Krabbe P, Weijnen T. Guidelines for analysing and reporting EQ-5D outcomes. In: Brooks R, Rabin R, de Charro F, eds. The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Dordrecht: Kluwer Academic Publishers 2003
   Google Scholar
• McDowell I, Newell C. Measuring Health: A Guide to Rating Scales and Questionnaires, 2nd edn. New York: Oxford University Press, 1996
   Google Scholar
• Jia H, Lubetkin EI. The impact of obesity on health-related quality-of-life in the general adult US population. J Public Health (Oxf) 2005;27:156–64
   PubMed Web of Science ®Google Scholar
• Redekop WK, Koopmanschap MA, Stolk RP, et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002;25:458–63
   PubMed Web of Science ®Google Scholar
• Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). UK Prospective Diabetes Study Group. Diabetes Care 1999;22:1125–36
   Google Scholar
• Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: Wenger NK, Mattson ME, Furberg CD, et al., eds. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Washington, DC: Le Jacq Publishing, 1984:170–83
   Google Scholar
• Chassany O, Dimenas E, Dubois D, et al. PGWBI User Manual. Lyon, France: MAPI Research Institute, 2004
   Google Scholar
• Leonardson GR, Daniels MC, Ness FK, et al. Validity and reliability of the general well-being schedule with northern plains American Indians diagnosed with type 2 diabetes mellitus. Psychol Rep 2003;93:49–58
   PubMed Web of Science ®Google Scholar
• Matza LS, Secnik K, Rentz AM, et al. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report. Qual Life Res 2005;14:735–47
   PubMed Web of Science ®Google Scholar
• Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord 1998;48: 25–36
   PubMed Web of Science ®Google Scholar
• Secnik K, Matza LS, Cottrell S, et al. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Med Decis Making 2005;25:56–70
   PubMed Web of Science ®Google Scholar
• Bass EB, Steinberg EP, Pitt HA, et al. Comparison of the rating scale and the standard gamble in measuring patient preferences for outcomes of gallstone disease. Med Decis Making 1994;14:307–14
   PubMed Web of Science ®Google Scholar
• Cook J, Richardson J, Street A. A cost utility analysis of treatment options for gallstone disease: methodological issues and results. Health Econ 1994;3:157–68
   Google Scholar
• Feeny DH, Torrance GW. Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples. Med Care 1989;27 (Suppl 3):S190–204
   Web of Science ®Google Scholar
• Johnson JA, Coons SJ, Ergo A, et al. Valuation of EuroQOL (EQ-5D) health states in an adult U.S. sample. Pharmacoeconomics 1998;13:421–33
   PubMed Web of Science ®Google Scholar
• Stalmeier PF. Discrepancies between chained and classic utilities induced by anchoring with occasional adjustments. Med Decis Making 2002;22:53–64
   PubMed Web of Science ®Google Scholar
• Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999;282: 1523–9
   PubMed Web of Science ®Google Scholar
• Villareal DT, Apovian CM, Kushner RF, et al. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Obes Res 2005;13:1849–63
   PubMedGoogle Scholar
• Wardle J, Waller J, Jarvis MJ. Sex differences in the association of socioeconomic status with obesity. Am J Public Health 2002;92:1299–304
   Google Scholar
• Foxcroft DR, Milne R. Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. Obes Rev 2000;1:121–6
   PubMedGoogle Scholar
• Groessl EJ, Kaplan RM, Barrett-Connor E, et al. Body mass index and quality of well-being in a community of older adults. Am J Prev Med 2004;26:126–9
   Google Scholar
• Hakim Z, Wolf A, Garrison LP. Estimating the effect of changes in body mass index on health state preferences. Pharmaco-economics 2002;20:393–404
   Google Scholar
• Kortt MA, Clarke PM. Estimating utility values for health states of overweight and obese individuals using the SF-36. Qual Life Res 2005;14:2177–85
   PubMed Web of Science ®Google Scholar
• Trakas K, Oh PI, Singh S, et al. The health status of obese individuals in Canada. Int J Obes Relat Metab Disord 2001;25:662–8
   PubMed Web of Science ®Google Scholar
• Torrance GW. Preferences for health outcomes and cost-utility analysis. Am J Manag Care 1997;3:S8–S20
   PubMed Web of Science ®Google Scholar
• Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. 2nd edn. Oxford, UK: Oxford University Press, 2000
   Google Scholar